Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma
NCT05093231Phase 2Active, not recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Feb 2025
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in pancreatic adenocarcinoma (PDAC), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Feb 2025; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05093231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093231.